The Israeli biotechnology startup Nectin Therapeutics has received a $10 million investment from the Guangzhou-Israel Biotechnology Fund. It creates innovative targeted immunotherapies to combat immunological oncology treatment resistance that is authorised.
The money will be utilised to support it’s ongoing worldwide Phase 1 clinical trial for NTX1088, which targets PVR, as well as the preclinical development of its anti-drug conjugate portfolio. It’s portfolio of innovative immuno-oncology therapies will be further developed with the help of these funds.
Read also – Singapore-Based IN-D.ai Acquired by Intain
A clinical-stage biotechnology business called Nectin helps patients with liver cancer by using knowledge of the nectin pathways to create immunological oncology treatments. The company’s treatments could raise the bar for patient response rates and efficacy in treating a variety of tumours that are challenging to treat.
Read also – Egypt-based Fintech Swypex Secures a $4 Million In Seed Funding
Nectin’s technology uses a variety of new monoclonal antibodies and antibody-drug conjugates to target significant escape mechanisms of existing IO therapies. Funded by aMoon Fund, Peregrine Ventures, IBF, Integra Holdings, Myeloma Investment Fund (MIF), and Cancer Focus Fund, it is a privately held venture-backed startup.
Nectin Therapeutics CEO Fabian Tenenbaum said, “We are grateful for the support from GIBF which reflects the rapid advancement of our anti-PVR clinical program as well as the progress in our development of several ADC candidates. With this new investment we are looking forward to completing both the dose-escalation and dose-expansion trials for NTX1088 and continue our IND-enabling activities of our ADC assets. We value GIBF’s commitment to our mission of developing life-saving therapies and look forward to advancing innovative medicines to improve the lives of cancer patients.”
About Nectin
Nectin Therapeutics is a biotechnology firm that pioneers the development of next-generation immuno-oncology medicines with the goal of improving the quality of life for cancer patients.
